| 臺大學術典藏 |
2022-09-14T01:29:27Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-04-21T06:51:26Z |
Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: Geographic variations among 502 villages in southern Taiwan
|
Tsai M.-C.; Kee K.-M.; Chen Y.-D.; Lin L.-C.; Tsai L.-S.; Chen, Tony Hsiu Hsi; Lu S.-N. |
| 臺大學術典藏 |
2022-04-21T06:51:12Z |
Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults
|
Lu S.-N.; Wang J.-H.; Chen P.-F.; Tung H.-D.; Tseng P.-L.; Hung C.-H.; Kee K.-M.; Chen C.-H.; Chang K.-C.; Lee C.-M.; Changchien C.-S.; Chen Y.-D.; Tsai L.-S.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-21T06:51:08Z |
Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation
|
Chiang J.-C.; Lin C.-Y.; Wang J.-H.; Kee K.-M.; Chen P.-F.; Chen Y.-D.; Tsai L.-S.; Chen, Tony Hsiu Hsi; Lu S.-N. |
| 臺大學術典藏 |
2022-02-23T02:12:21Z |
Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus
|
Kuo Y.-H.; Kee K.-M.; Hung C.-H.; Lu S.-N.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:20Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus
|
Kuo Y.-H.; Kee K.-M.; Hung C.-H.; Lu S.-N.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:07Z |
Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-18T08:26:03Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; CHIEH-CHANG CHEN; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:23Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; CHUN-JEN LIU; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-09-04T06:10:54Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; JIA-HORNG KAO; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; JIA-HORNG KAO; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2021-08-03T07:10:53Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-05-24T07:20:29Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; CHEN-HUA LIU; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2021-04-26T01:47:25Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; MING-CHIH HO; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-25T07:00:59Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Yu-Yun Shao;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Hsu C.;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T08:01:12Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Chiun Hsu;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Chiun Hsu; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021 |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Tseng J.-H.; Ho M.-C.; Liao L.-Y.; Liang J.-D.; Wang C.-K.; Lee W.-C.; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Lee R.-C.; Liang P.-C.; Huang K.-W.; Hu J.-T.; Kee K.-M.; Lin C.-L.; Lu S.-N.; Wang J.-H.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; CHIEH-CHANG CHEN; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
